anti- ALDH5A1 antibody

Este producto es parte de ALDH - Aldehyde dehydrogenase family member
Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
anti- ALDH5A1 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab00297
tested applications
ELISA, WB, IHC

Description

Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid(GABA).

Documents del producto

Instrucciones
Descargar
Data sheet

Product specifications

CategoryPrimary Antibodies
Immunogen Targetaldehyde dehydrogenase 5 family, member A1
HostRabbit
Reactivityhuman,mouse,rat
Recommended DilutionWB: 1:500-1:5000; IHC: 1:20-1:200
Clonalitypolyclonal
ConjugationUnconjugated
IsotypeIgG
Observed MW51 kDa
Purity≥95% as determined by SDS-PAGE
PurificationImmunogen affinity purified
Size 1100µg
Formliquid
Tested ApplicationsELISA, WB, IHC
StoragePBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt IDP51649
Gene ID7915
AliasALDH5A1,SSADH
BackgroundAntibody anti-ALDH5A1
StatusRUO
NoteThis product is for research use only.

Descripción

ALDH5A1, also known as succinic semialdehyde dehydrogenase (SSADH), is a mitochondrial enzyme involved in the catabolism of gamma-aminobutyric acid (GABA), an important inhibitory neurotransmitter. ALDH5A1 catalyzes the oxidation of succinic semialdehyde (SSA) to succinate, a key intermediate in the tricarboxylic acid (TCA) cycle, linking GABA metabolism to cellular energy production. Mutations in ALDH5A1 result in succinic semialdehyde dehydrogenase deficiency, a rare autosomal recessive disorder that causes the accumulation of SSA and GABA, leading to neurological symptoms such as developmental delays, hypotonia, seizures, and ataxia. ALDH5A1 plays a crucial role in maintaining GABA homeostasis and preventing neurotoxicity. Its dysfunction highlights the importance of proper neurotransmitter balance and energy metabolism in neurological health. Therapies targeting ALDH5A1 function focus on reducing SSA accumulation and alleviating associated neurological impairments.

Related Products

EH1288

Human ALDH5A1(Succinate-semialdehyde dehydrogenase, mitochondrial) ELISA Kit

Ver Producto
FNab00297

anti- ALDH5A1 antibody

Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid(GABA).

Ver Producto
P5328

Recombinant Human ALDH5A1

Ver Producto